Abstract
There is extensive trial-based evidence showing that antihypertensive drugs reduce the risk of vascular events (e.g. stroke and myocardial infarction) as well as target organ damage (e.g. left ventricular hypertrophy and microalbuminuria). However, some of these benefits appear to be, at least partially, independent of the extent of blood pressure (BP) lowering. It is also evident that in certain clinical situations some antihypertensive drugs are more effective than others. In this review we discuss the effects of antihypertensive drugs on the endothelium, platelets, fibrinolysis and coagulation. These properties may account for the observed BP-independent actions. Antihypertensive drugs exert multiple effects on the vascular endothelium. These include effects on nitric oxide (NO) and angiotensin II-mediated actions. Many BP lowering drugs can inhibit platelet activity, although the relevance of this property is unknown, especially if patients are also taking platelet inhibitors (e.g. aspirin). Antihypertensive drugs also influence fibrinolysis and coagulation. These effects may be mediated by a variety of mechanisms, including altering insulin sensitivity. The haemostatic actions of antihypertensive drugs deserve greater recognition and further investigation.
Keywords: angiotensin, antihypertensive drugs, coagulation, endothelium, fibrinolysis, haemostasis, nitric oxide, platelets
Current Pharmaceutical Design
Title: The Effects of Antihypertensive Therapy on Haemostatic Parameters
Volume: 9 Issue: 29
Author(s): E. S. Ganotakis, J. A. Papadakis, G. E. Vrentzos and D. P. Mikhailidis
Affiliation:
Keywords: angiotensin, antihypertensive drugs, coagulation, endothelium, fibrinolysis, haemostasis, nitric oxide, platelets
Abstract: There is extensive trial-based evidence showing that antihypertensive drugs reduce the risk of vascular events (e.g. stroke and myocardial infarction) as well as target organ damage (e.g. left ventricular hypertrophy and microalbuminuria). However, some of these benefits appear to be, at least partially, independent of the extent of blood pressure (BP) lowering. It is also evident that in certain clinical situations some antihypertensive drugs are more effective than others. In this review we discuss the effects of antihypertensive drugs on the endothelium, platelets, fibrinolysis and coagulation. These properties may account for the observed BP-independent actions. Antihypertensive drugs exert multiple effects on the vascular endothelium. These include effects on nitric oxide (NO) and angiotensin II-mediated actions. Many BP lowering drugs can inhibit platelet activity, although the relevance of this property is unknown, especially if patients are also taking platelet inhibitors (e.g. aspirin). Antihypertensive drugs also influence fibrinolysis and coagulation. These effects may be mediated by a variety of mechanisms, including altering insulin sensitivity. The haemostatic actions of antihypertensive drugs deserve greater recognition and further investigation.
Export Options
About this article
Cite this article as:
Ganotakis S. E., Papadakis A. J., Vrentzos E. G. and Mikhailidis P. D., The Effects of Antihypertensive Therapy on Haemostatic Parameters, Current Pharmaceutical Design 2003; 9 (29) . https://dx.doi.org/10.2174/1381612033453839
DOI https://dx.doi.org/10.2174/1381612033453839 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Current Alzheimer Research Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Periodontitis and Atherosclerosis, a Causal Relationship?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Evaluation of the Food and Nutrition Value of Rubus alceifolius Poir. Fruits of Mizoram, India
Current Nutrition & Food Science Editorial [Hot Topic: Cardiovascular Diagnostic Testing: Use and Limits of Biochemical Markers (Executive Editors: Aurelio Leone and Stefano Taddei)]
Current Pharmaceutical Design The Future of Diabetes Management by Healthy Probiotic Microorganisms
Current Diabetes Reviews Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Current Vascular Pharmacology Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design Using Bioinformatics Techniques for Gene Identification in Drug Discovery and Development
Current Drug Metabolism Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Biomarkers in Post-stroke Depression
Current Neurovascular Research Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder
Current Alzheimer Research Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews Inflammatory Biomarkers in Atrial Fibrillation
Current Medicinal Chemistry Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design